Kalaris Therapeutics, Inc.

Developing next-gen, long-acting anti-VEGF therapies for prevalent retinal diseases.

KLRS | NDAQ

Overview

Corporate Details

ISIN(s):: US0198181036
LEI:
Country:: United States of America
Address:: 628 MIDDLEFIELD ROAD, 94301 PALO ALTO
Website:: https://kalaristx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing treatments for prevalent retinal diseases. The company's lead product candidate is TH103, a fully humanized, recombinant fusion protein designed as a next-generation anti-VEGF agent for intravitreal delivery. Co-developed by Dr. Napoleone Ferrara, known for his work on Avastin and Lucentis, TH103 acts as a soluble decoy receptor. A key feature is its high affinity for heparan sulfate proteoglycans (HSPG), which may act as a molecular anchor to extend its intraocular retention. This mechanism aims to reduce the frequency of injections for patients with neovascular retinal diseases, such as age-related macular degeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kalaris Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kalaris Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kalaris Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
ELUTIA INC. Develops drug-eluting biologics to reduce complications from medical implants.	United States of America	ELUT
Emergent BioSolutions Inc. Develops and manufactures medical countermeasures for public health and national security threats.	United States of America	EBS
ENANTA PHARMACEUTICALS INC Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.	United States of America	ENTA
enGene Holdings Inc. Developing non-viral, locally administered gene therapies for rare genetic conditions.	United States of America	ENGN
Enliven Therapeutics, Inc. A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.	United States of America	ELVN
Enlivex Therapeutics Ltd. Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.	Israel	ENLV
Enlivex Therapeutics Ltd. Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.	United States of America	ENLV
Enorama Pharma AB Develops & makes consumer nicotine products & medicated gums, offering private label solutions.	Sweden	ERMA
Ensysce Biosciences, Inc. Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.	United States of America	ENSC
Entera Bio Ltd. Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.	United States of America	ENTX